Protalix BioTherapeutics (PLX) Tops Q1 EPS by 18c ; Offers Guidance
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.22 -5.93%
Revenue Growth %: -49.8%
Financial Fact:
REVENUES: 4.67M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Revenue Growth %: -49.8%
Financial Fact:
REVENUES: 4.67M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q1 EPS of $0.22, $0.18 better than the analyst estimate of $0.04. Revenue for the quarter came in at $33.75 million versus the consensus estimate of $18.7 million.
GUIDANCE:
Protalix BioTherapeutics sees FY2026 revenue of $78-83 million, versus the consensus of $79.1 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Movano (MOVE) Misses Q2 EPS by 195c
- Phillips 66, Marathon Merger Talks Collapsed - Semafor
- SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
